Skip to main content
. 2020 Apr 9;50(2):433–441. doi: 10.3906/sag-1912-62

Figure.

Figure

Comparison of OCS dosage (A), number of asthma exacerbations (B), ACT (C), FEV1 (D), and blood eosinophils (E) at the beginning of mepolizumab and at the 12th and 24th weeks after beginning treatment.